Liraglutide 3.0 mg trial investigates gut microbiome's role in obesity weight loss
Effect of Liraglutide on Microbiome in Obesity
Abstract
A randomized, double-blind, placebo-controlled trial is evaluating if Liraglutide 3.0 mg's weight loss effects in obesity are mediated by gut microbiome changes.